USPTO serial 99735617
RETRO BIOSCIENCES
Status 641Office Action
- Filing date
- Mar 31, 2026
- Status date
- Aug 18, 2026
- Registration date
- —
- Examiner
- CLYBURN, CARLA DIONNE
Need help with RETRO BIOSCIENCES?
CopyMark Law Group can help you respond to USPTO correspondence, keep a registration alive, or watch new filings against your mark.
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Deadline: November 18, 2026
Office Action issues
The USPTO examiner issued a likelihood of confusion refusal with existing registrations, required a disclaimer of the term 'BIOSCIENCES', and refused the current specimen for class 5.
Owner
Retro Biosciences, Inc.
Redwood City, CA, US
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Therapeutic pharmaceutical for the treatment of diseases and conditions associated with aging | ACTIVE | Apr 5, 2022 |
| 042 | Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Development of pharmaceuticals for cell and gene therapies; Research and development of new products in the field of pharmaceuticals; Research of induced pluripotent stem cells | ACTIVE | Apr 5, 2022 |
Prosecution history
| Date | Code | Event |
|---|---|---|
| Aug 18, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Aug 18, 2026 | GNRT | NON-FINAL ACTION E-MAILED |
| Aug 18, 2026 | CNRT | NON-FINAL ACTION WRITTEN |
| Aug 13, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Aug 13, 2026 | GNRT | NON-FINAL ACTION E-MAILED |
| Aug 13, 2026 | CNRT | NON-FINAL ACTION WRITTEN |
| Aug 10, 2026 | DOCK | ASSIGNED TO EXAMINER |
| Jul 29, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Mar 31, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED |
| Mar 31, 2026 | NWAP | NEW APPLICATION ENTERED |